GSK plc (GSK) Stock Competitors & Peer Comparison
See (GSK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $51.52 | +0.49% | 103.7B | 13.50 | $3.82 | +3.49% |
| LLY | $1,131.42 | +0.55% | 1.1T | 40.25 | $28.13 | +0.57% |
| JNJ | $232.77 | +2.02% | 560.3B | 26.97 | $8.63 | +2.25% |
| ABBV | $227.23 | +1.02% | 401.3B | 111.33 | $2.04 | +2.96% |
| MRK | $120.79 | +0.44% | 298.5B | 33.95 | $3.56 | +2.73% |
| AZN | $185.95 | +2.28% | 288.4B | 27.96 | $6.65 | +1.73% |
| NVS | $149.16 | +0.51% | 284.5B | 21.39 | $6.97 | +3.19% |
| AMGN | $349.58 | +1.15% | 188.7B | 24.31 | $14.38 | +2.78% |
| GILD | $129.16 | -0.02% | 160.4B | 15.43 | $8.37 | +2.46% |
| PFE | $26.04 | +1.36% | 148.4B | 19.88 | $1.31 | +6.62% |
Stock Comparison
GSK vs LLY Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GSK is priced at $51.52, while LLY trades at $1,131.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas LLY's P/E ratio is 40.25. In terms of profitability, GSK's ROE is +0.28%, compared to LLY's ROE of +1.01%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
GSK vs JNJ Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, JNJ has a market cap of 560.3B. Regarding current trading prices, GSK is priced at $51.52, while JNJ trades at $232.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas JNJ's P/E ratio is 26.97. In terms of profitability, GSK's ROE is +0.28%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GSK is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
GSK vs ABBV Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, ABBV has a market cap of 401.3B. Regarding current trading prices, GSK is priced at $51.52, while ABBV trades at $227.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas ABBV's P/E ratio is 111.33. In terms of profitability, GSK's ROE is +0.28%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, GSK is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
GSK vs MRK Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, MRK has a market cap of 298.5B. Regarding current trading prices, GSK is priced at $51.52, while MRK trades at $120.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas MRK's P/E ratio is 33.95. In terms of profitability, GSK's ROE is +0.28%, compared to MRK's ROE of +0.18%. Regarding short-term risk, GSK is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
GSK vs AZN Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, AZN has a market cap of 288.4B. Regarding current trading prices, GSK is priced at $51.52, while AZN trades at $185.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas AZN's P/E ratio is 27.96. In terms of profitability, GSK's ROE is +0.28%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GSK is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
GSK vs NVS Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, NVS has a market cap of 284.5B. Regarding current trading prices, GSK is priced at $51.52, while NVS trades at $149.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas NVS's P/E ratio is 21.39. In terms of profitability, GSK's ROE is +0.28%, compared to NVS's ROE of +0.32%. Regarding short-term risk, GSK is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
GSK vs AMGN Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, AMGN has a market cap of 188.7B. Regarding current trading prices, GSK is priced at $51.52, while AMGN trades at $349.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas AMGN's P/E ratio is 24.31. In terms of profitability, GSK's ROE is +0.28%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
GSK vs GILD Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, GILD has a market cap of 160.4B. Regarding current trading prices, GSK is priced at $51.52, while GILD trades at $129.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas GILD's P/E ratio is 15.43. In terms of profitability, GSK's ROE is +0.28%, compared to GILD's ROE of +0.42%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
GSK vs PFE Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, PFE has a market cap of 148.4B. Regarding current trading prices, GSK is priced at $51.52, while PFE trades at $26.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas PFE's P/E ratio is 19.88. In terms of profitability, GSK's ROE is +0.28%, compared to PFE's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
GSK vs BMY Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, BMY has a market cap of 116.9B. Regarding current trading prices, GSK is priced at $51.52, while BMY trades at $57.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas BMY's P/E ratio is 16.04. In terms of profitability, GSK's ROE is +0.28%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
GSK vs SNY Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SNY has a market cap of 108.4B. Regarding current trading prices, GSK is priced at $51.52, while SNY trades at $45.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas SNY's P/E ratio is 19.49. In terms of profitability, GSK's ROE is +0.28%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
GSK vs ZTS Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, ZTS has a market cap of 33.3B. Regarding current trading prices, GSK is priced at $51.52, while ZTS trades at $79.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas ZTS's P/E ratio is 13.02. In terms of profitability, GSK's ROE is +0.28%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, GSK is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ZTS's competition here
GSK vs BIIB Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, BIIB has a market cap of 28.8B. Regarding current trading prices, GSK is priced at $51.52, while BIIB trades at $195.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas BIIB's P/E ratio is 20.98. In terms of profitability, GSK's ROE is +0.28%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
GSK vs HZNP Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $51.52, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.28%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
GSK vs GRFS Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, GRFS has a market cap of 6.5B. Regarding current trading prices, GSK is priced at $51.52, while GRFS trades at $7.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas GRFS's P/E ratio is 10.76. In terms of profitability, GSK's ROE is +0.28%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
GSK vs OGN Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, GSK is priced at $51.52, while OGN trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas OGN's P/E ratio is 14.38. In terms of profitability, GSK's ROE is +0.28%, compared to OGN's ROE of +0.30%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
GSK vs CELG-RI Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, CELG-RI has a market cap of 203.6M. Regarding current trading prices, GSK is priced at $51.52, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CELG-RI's competition here
GSK vs CTOR Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, CTOR has a market cap of 72.5M. Regarding current trading prices, GSK is priced at $51.52, while CTOR trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas CTOR's P/E ratio is -1.63. In terms of profitability, GSK's ROE is +0.28%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, GSK is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CTOR's competition here
GSK vs SCLX Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SCLX has a market cap of 59.4M. Regarding current trading prices, GSK is priced at $51.52, while SCLX trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas SCLX's P/E ratio is -0.17. In terms of profitability, GSK's ROE is +0.28%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
GSK vs MIRA Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, MIRA has a market cap of 42M. Regarding current trading prices, GSK is priced at $51.52, while MIRA trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas MIRA's P/E ratio is -0.79. In terms of profitability, GSK's ROE is +0.28%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
GSK vs SRXH Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, GSK is priced at $51.52, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas SRXH's P/E ratio is -0.71. In terms of profitability, GSK's ROE is +0.28%, compared to SRXH's ROE of +8.75%. Regarding short-term risk, GSK is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SRXH's competition here
GSK vs SCLXW Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, GSK is priced at $51.52, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GSK is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
GSK vs CRXT Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $51.52, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.28%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here
GSK vs BDSIW Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $51.52, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.50, whereas BDSIW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here